Tretinoin/benzoyl peroxide

Tretinoin/benzoyl peroxide
Combination of
TretinoinRetinoid
Benzoyl peroxideOxidizing agent
Clinical data
Trade namesTwyneo
Other namesS6G5T-3
License data
Routes of
administration		Topical
ATC code
Legal status
Legal status
Identifiers
KEGG

Tretinoin/benzoyl peroxide, sold under the brand name Twyneo, is a fixed-dose combination medication used for the treatment of acne.[1][2] It contains tretinoin, a vitamin A derivative, and benzoyl peroxide, an oxidizing agent.[3]

The U.S. Food and Drug Administration (FDA) approved this medication for use in July 2021.[2][4][5] Historically, the co-formulation of these two active ingredients was avoided because benzoyl peroxide typically causes the oxidative degradation of tretinoin when stored together.[6] To address this stability issue, Twyneo employs a silica-based sol-gel microencapsulation technology, which serves as a physical barrier that prevents the benzoyl peroxide from damaging the tretinoin within the vehicle.[7]

References

  1. ^ a b "Twyneo (tretinoin and benzoyl peroxide) cream, for topical use" (PDF). U.S. Food and Drug Administration. Archived from the original (PDF) on 28 July 2021.
  2. ^ a b "Sol-Gel Technologies Announces FDA Approval of Twyneo" (Press release). Sol-Gel Technologies Ltd. 27 July 2021. Retrieved 27 July 2021 – via GlobeNewswire.
  3. ^ Ochsendorf F (June 2015). "Clindamycin phosphate 1.2% / tretinoin 0.025%: a novel fixed-dose combination treatment for acne vulgaris". Journal of the European Academy of Dermatology and Venereology. 29 (Suppl 5): 8–13. doi:10.1111/jdv.13185. PMID 26059820. S2CID 29681121.
  4. ^ "Twyneo: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Archived from the original on 28 July 2021. Retrieved 27 July 2021.
  5. ^ "NDA Approval: Twyneo" (PDF). U.S. Food and Drug Administration. 26 July 2021.
  6. ^ Martin B, Meunier C, Montels D, Watts O (October 1998). "Chemical stability of adapalene and tretinoin when combined with benzoyl peroxide in presence and in absence of visible light and ultraviolet radiation". The British Journal of Dermatology. 139 (Suppl 52). Wiley: 8–11. doi:10.1046/j.1365-2133.1998.1390s2008.x. PMID 9990414. S2CID 43287596.
  7. ^ Green LJ, Bhatia ND, Toledano O, Erlich M, Spizuoco A, Goodyear BC, York JP, Jakus J (December 2023). "Silica-based microencapsulation used in topical dermatologic applications". Archives of Dermatological Research. 315 (10): 2787–2793. doi:10.1007/s00403-023-02725-z. PMC 10616207. PMID 37792034.


This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.